Metformin drug used in PCOS treatment can decrease hepatic gluconeogenesis by different mechanisms [22]: delay intestinal glucose absorption [23], reshape microbiota in the intestine [24,25], increase insulin-mediated glucose uptake in the liver, visceral fat, and muscle [26], and stimulates insulin signaling pathway in human granulosa cells and other cells of the body [27]. The gene discussed is INS; the disease is polycystic ovary syndrome.